| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Boc-L-Ala-OH-d3 does not have a classical biological receptor target; it is a protected amino acid that serves as a substrate for peptide coupling reactions and can be incorporated into peptides that interact with various receptors. Its primary application is as a synthetic intermediate, and any biological activity is attributable to the alanine-containing peptide product rather than the protected building block itself.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, Boc-L-Ala-OH-d3 is used in solid-phase peptide synthesis and solution-phase coupling reactions, where the deuterium label enables mass spectrometric tracking of incorporation efficiency; it enables orthogonal Boc/Bzl protection strategies and suppresses aggregation during peptide chain elongation, but it does not exhibit intrinsic receptor agonist or antagonist activity. |
| ln Vivo |
In vivo, Boc-L-Ala-OH-d3 is not administered as a therapeutic agent; it is used as a synthetic building block and analytical tracer, and any in vivo data relate to the biological effects of alanine-containing peptides rather than to the protected amino acid itself, with no established pharmacokinetic or efficacy profile.
|
| Enzyme Assay |
Noncellular assays for Boc-L-Ala-OH-d3 include HPLC or LC-MS/MS quantification of coupling efficiency and purity during peptide synthesis, chiral purity analysis by chiral chromatography, and stability testing under acidic and basic conditions; the deuterated form serves as an internal standard for quantification of the protected amino acid in reaction mixtures.
|
| Cell Assay |
Cellular assays are not typically used for Boc-L-Ala-OH-d3 because it is a synthetic intermediate; if biological activity is assessed, alanine-containing peptides are tested in cell-based assays, but the protected amino acid itself is not a bioactive ligand in cell culture systems.
|
| Animal Protocol |
Animal protocols are not used for Boc-L-Ala-OH-d3 because it is not a therapeutic candidate; it is used in peptide synthesis and analytical chemistry, and any in vivo studies would involve the peptides synthesized with this building block rather than the protected amino acid itself.
|
| References |
| Molecular Formula |
C8H15NO4
|
|---|---|
| Molecular Weight |
189.209
|
| Exact Mass |
192.118
|
| CAS # |
161602-47-7
|
| Related CAS # |
Boc-L-Ala-OH;15761-38-3
|
| PubChem CID |
10081291
|
| Appearance |
Solid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
320.9±25.0 °C at 760 mmHg
|
| Melting Point |
79-83ºC(lit.)
|
| Flash Point |
147.9±23.2 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.460
|
| LogP |
1.1
|
| tPSA |
75.63
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
13
|
| Complexity |
207
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(OC(N[C@@H](C([2H])([2H])[2H])C(=O)O)=O)(C)C
|
| InChi Key |
QVHJQCGUWFKTSE-MQBGRFPLSA-N
|
| InChi Code |
InChI=1S/C8H15NO4/c1-5(6(10)11)9-7(12)13-8(2,3)4/h5H,1-4H3,(H,9,12)(H,10,11)/t5-/m0/s1/i1D3
|
| Chemical Name |
(2S)-3,3,3-trideuterio-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2851 mL | 26.4257 mL | 52.8513 mL | |
| 5 mM | 1.0570 mL | 5.2851 mL | 10.5703 mL | |
| 10 mM | 0.5285 mL | 2.6426 mL | 5.2851 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
